Company: TBPH
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001104659-25-033819
Chunk: 43

Company: Theravance Biopharma, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 43
---
 Mr. Broshy (97,620); Dr. Malkiel (74,044); Mr. Mitchell (97,620); Mr. O’Connor (109,620); Dr. Pakianathan (96,620); Dr. Smaldone Alsup (111,120); Ms. Gray (78,286); and Mr. Grant (49,888). Mr. Kelly held no outstanding options to purchase our ordinary shares. (5) Dr. Malkiel did not stand for re-election in 2024. Non-Employee Director Share Ownership Guidelines Pursuant to our share ownership guidelines, beginning on the later of January 1, 2023 or after five years of service, non-employee directors are expected to hold shares (including vested and unvested RSUs) with a value equal to at least five times their annual base cash retainer. All non-employee members of our board of directors are in compliance with our non-employee director share ownership guidelines, with the exception of non-employee members of our board of directors who do not yet have sufficient tenure to require compliance with such guidelines. Insider Trading and Hedging Policy Disclosure Pursuant to our insider trading policy, all our directors, officers, employees and agents (such as consultants and independent contractors) as well as the members of their immediate family, persons with whom they share a household, persons that are their economic dependents and any other individuals or entities whose transactions in securities they influence, direct or control are prohibited from engaging in transactions in publicly-traded options on our securities, such as puts, calls and other derivative securities, on an exchange or in any other organized market. Although our Insider Trading Policy requires that all such individuals receive permission from one of our senior legal officers before entering into any hedging or monetization transactions, we have not and do not intend to in the future approve any such transactions. The full text of our insider trading policy is posted on the Investor Relations portion of our website at www.theravance.com and is filed as Exhibit 19.1 to our Annual Report on Form 10-K for the fiscal year ended December 31, 2024. Shareholder Communications with the Board of Directors Shareholders interested in communicating with the board of directors or a particular director should send correspondence to Theravance Biopharma, Inc., c/o of its U.S. subsidiary, Theravance Biopharma US, LLC, at 901 Gateway Boulevard, South San Francisco, California 94080, Attn: Secretary. Each communication